MedComm-Oncology

MedComm-Oncology is an open access peer-reviewed journal published by Wiley since 2023 under the ISSN 2769-6448 as a sister title to MedComm, covering oncology and cancer biology with a 2025 Journal Impact Factor of 8.5 and a first quartile rank of 40 of 333 in oncology in the Emerging Sources Citation Index《医学通讯肿瘤学》（MedComm-Oncology）是（Wiley）自 2023 年起出版的开放获取同行评审期刊，刊号 2769-6448，为《医学通讯》（MedComm）的姊妹刊，覆盖肿瘤学与癌症生物学，2025 年影响因子为 8.5，在（ESCI）肿瘤学类 333 种期刊中列第 40 位、居第一四分位。

Scope

• The journal publishes original research, reviews and clinical studies on oncology and cancer biology, including tumor biology, cancer immunology, targeted therapy, drug resistance and cancer biomarkers该刊刊载肿瘤学与癌症生物学领域的原创研究、综述与临床研究，涉及肿瘤生物学、肿瘤免疫学、靶向治疗、耐药机制与癌症生物标志物等方向。
• It gives particular attention to translational oncology that links laboratory discoveries to clinical applications, and it welcomes interdisciplinary work connecting cancer research with immunology, pharmacology and genomics该刊特别关注将实验室发现与临床应用相连的转化肿瘤学，并欢迎癌症研究与免疫学、药理学及基因组学交叉的研究。
• Article types include research articles, reviews, short communications, case reports and perspectives, and the journal operates a continuous publication model with articles assigned to a single annual volume文章类型包括研究论文、综述、短通讯、病例报告与观点，该刊采用连续出版模式，文章归入单一年度卷。
• As an open access journal it applies a Creative Commons attribution licence to accepted articles and levies an article processing charge on the corresponding author, with waivers available for qualifying authors作为开放获取期刊，该刊对录用文章采用知识共享署名许可，向通讯作者收取文章处理费，并对符合条件的作者提供减免。
• Peer review is conducted single-blind and the journal follows the Wiley editorial policies on data availability, research integrity and competing interests同行评审采用单盲方式，该刊遵循（Wiley）关于数据可获取性、研究诚信与利益冲突的编辑政策。
• The journal is abstracted and indexed in the Emerging Sources Citation Index, Scopus, PubMed Central and the Directory of Open Access Journals, and it is included in the Journal Citation Reports from the 2024 edition onwards该刊被（Emerging Sources Citation Index）、（Scopus）、（PubMed Central）与开放获取期刊目录收录，并自 2024 年版起纳入期刊引证报告。

History

• The journal was launched in 2023 by Wiley as a companion to MedComm, the flagship open access medical journal founded in 2020 in collaboration with the Second Affiliated Hospital of Zhejiang University School of Medicine该刊于 2023 年由（Wiley）创办，作为《医学通讯》的姊妹刊，后者是 2020 年联合浙江大学医学院附属第二医院创办的旗舰开放获取医学刊。
• It was conceived to provide a dedicated oncology venue as the parent title broadened its medical scope, and its founding editorial board drew members from cancer hospitals and research institutes in China and abroad该刊定位为在母刊扩展医学范围之际为肿瘤学提供专门平台，首届编委来自中国与海外的癌症医院及研究机构。
• From its first year the journal operated as a gold open access title with a Creative Commons licence, and it has retained the continuous publication model since launch自创刊起该刊即为金色开放获取期刊，采用知识共享许可，并一直沿用连续出版模式。
• The Journal Impact Factor was first reported as 2.2 in 2024 and rose to 8.5 in 2025, placing the journal in the first quartile of oncology该刊的影响因子在 2024 年版首报 2.2，2025 年版升至 8.5，居肿瘤学类第一四分位。
• The publisher carries the journal on the Wiley Online Library platform and the digital object identifier prefix of its articles is 10.1002, shared with other Wiley medical and life science journals出版方将该刊载于（Wiley Online Library）平台，其文章的数字对象唯一标识符前缀为（10.1002），与（Wiley）其他医学与生命科学期刊一致。

Editors

• The journal is led by an editor-in-chief supported by an international editorial board whose members are drawn from cancer centres, medical schools and research institutes across the world该刊由一位主编带领，配以由世界各地癌症中心、医学院及研究机构学者组成的国际编委会。
• The editorial board includes section editors responsible for subject areas such as tumor biology, cancer immunology, targeted therapy and clinical oncology, reflecting the scope of the journal编委会设有学科编辑，分别负责肿瘤生物学、肿瘤免疫学、靶向治疗与临床肿瘤学等方向，对应刊物的定位。
• Editorial handling follows the Wiley editorial management system, with submissions assigned to handling editors based on subject expertise and competing interest declarations稿件处理依托（Wiley）的编辑管理系统，依据学科专长与利益冲突声明分配责任编辑。
• Peer review is conducted single-blind and the journal maintains the Wiley standards on reviewer recruitment, conflict of interest management, data sharing and editorial independence同行评审采用单盲方式，该刊遵循（Wiley）在审稿人遴选、利益冲突管理、数据共享与编辑独立性方面的标准。
• The masthead and board roster are published on the journal page at Wiley Online Library and updated as new members join or existing members step down编委名单在（Wiley Online Library）期刊页公布，并随成员增减而更新。